Company Overview: OPK

Upcoming Projects (OPK)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (OPK)

A Second Look: Discussing the diagnosis process for prostate cancer and the use of the Prostate Health Index test (PHI) and the 4Kscore Test.
Tickers: OPK, DHR, cleveland diagnostics
Executed On: Nov 29, 2023 at 09:30 AM EST
Discussing the diagnosis process for prostate cancer and the use of the Prostate Health Index test (PHI) and the 4Kscore Test.
Tickers: OPK, DHR, cleveland diagnostics
Executed On: Nov 22, 2023 at 01:00 PM EST

Expired Projects (OPK)

Following Recent Completion of Clinical Study for PSA test and with upcoming modular PMA to FDA, We Take a Deeper Look at OPKO Health’s Claros 1 Point of Care Testing Device
Tickers: OPK, ALR
Execute By: Jan 12, 2018

Upcoming & Overdue Catalysts (OPK)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (OPK)

Opko study of its CTAP101 capsules in treating patients with bone metastases caused by breast or prostate cancer set for December 2018 completion date
Ticker: OPK
Occurred on: Sep 27, 2019
Long Term (4year) Data Released of Phase 3 Study for Opko's (OPK) Somatrogon (hGH-CTP), an Investigational Long-Acting Growth Hormone Being Studied for the Treatment of Children With Growth Hormone Deficiency
Ticker: OPK
Occurred on: Sep 23, 2019
Opko (OPK) commences Phase 3 trial for hGH-CTP in pediatric patients; company preparing for BLA submisison
Ticker: OPK
Occurred on: Aug 29, 2019
OPKO (OPK) Announces Topline Results In Phase 2 of Oxyntomodulin (OPK88003) Diabetes And Obesity Trial
Ticker: OPK
Occurred on: Mar 21, 2019
OPK's Phase 1/2a Study to Assess FVIIa (MOD-5014) in Adult Men With Hemophilia A or B set for March 2017 primary completion date
Ticker: OPK
Occurred on: Sep 28, 2018
Opko (OPK) to initiate Phase 2 trial for RAYALDEE for Stage 5 CKD patients with SHPT during second Q4 2017
Tickers: OPK, Vifor Fresenius
Occurred on: Sep 04, 2018
Opko Biologics (OPKO) Phase 1 study to evaluate safety and efficacy of VIIa (MOD-5014) in males
Ticker: OPK
Occurred on: May 04, 2018
Opko (OPK) to begin phase 2b trial on TT401—an oxytomodulin dual GLP1/Glucagon agonist for diabetes and obesity—in early 2018
Ticker: OPK
Occurred on: Mar 23, 2018
In Q4 2017, Opko (OPK) to commence Phase 2b trial to test TT701 (OPK88004) ability to reduce prostate size, increase muscle mass and bone strength, and decrease fat mass in men with enlarged prostate (BPH)
Ticker: OPK
Occurred on: Nov 27, 2017
OPKO to commence second study of its POC test in 2017, which will be followed by a 510(k) submission in late-2017
Ticker: OPK
Occurred on: Nov 08, 2017
PMA filing for Opko (OPK) POC diagnostic test set for first half of 2017, with FDA application to follow
Ticker: OPK
Occurred on: Nov 07, 2017
Opko (OPK) commenced study of its Claros POC diagnostic test for prostate specific antigen (PSA), with FDA application expected mid-2017
Ticker: OPK
Occurred on: Nov 07, 2017
Phase 3 data of hGH-CTP in adults with growth hormone deficiency likely due 2H 2016
Ticker: OPK
Occurred on: Dec 30, 2016
OPKO (OPK) Announces U.S. Launch of RAYALDEE
Ticker: OPK
Occurred on: Nov 23, 2016
OPKO Presents Data on RAYALDEE at ASN Kidney Week 2016
Ticker: OPK
Occurred on: Nov 17, 2016
OPKO to Present Long-acting Human Growth Hormone (hGH-CTP) Phase 2 Pediatric Growth Hormone Deficiency Data at the 55th Annual Meeting of the European Society for Paediatric Endocrinology
Ticker: OPK
Occurred on: Sep 12, 2016
A six month review period has been assigned for the resubmitted RAYALDEE NDA, and the new PDUFA date will be October 22, 2016
Ticker: OPK
Occurred on: Jun 21, 2016
OPKO Presents Additional Data on RAYALDEE at National Kidney Foundation Spring Clinical Meetings 2016
Ticker: OPK
Occurred on: Apr 28, 2016
FDA Accepts Resubmission of New Drug Application for RAYALDEE
Ticker: OPK
Occurred on: Apr 27, 2016
PDUFA date set for March 29 2016 for Rayaldee in treating Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) and vitamin D insufficiency
Ticker: OPK
Occurred on: Mar 30, 2016
OPKO Health Announces Dosing of First Patient in Phase 2a Clinical Study of a Long-Acting Factor VIIa for the Treatment of Hemophilia
Ticker: OPK
Occurred on: Feb 23, 2016
Study Demonstrates OPKO's 4Kscore Test Reduces Unnecessary Prostate Biopsies While Improving Risk Prediction for Aggressive Prostate Cancer
Ticker: OPK
Occurred on: Feb 09, 2016
Conversion Right Extended on OPKO 3.0% Convertible Senior Notes
Ticker: OPK
Occurred on: Jan 05, 2016

Strategic Initiatives (OPK)

OPKO Health’s GeneDx Enters into Agreement with Pediatrix Medical Group to Offer Neonatal Genomic Services
Ticker: OPK
Announcement Date: Aug 12, 2020
OPKO Health to Acquire Transition Therapeutics
Tickers: OPK, TTHI
Announcement Date: Jun 30, 2016

OPK Overview